产品名称
Anti-Synuclein α Antibody, Chemicon®, from sheep
biological source
sheep
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin), western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... SNCA(6622)
Immunogen
Synthetic peptide corresponding amino acids 116-131 of human alpha synuclein.
Application
Detect Synuclein using this Anti-Synuclein Antibody, α validated for use in WB, IH(P).
Immunohistochemistry: 0.5-1 μg/mL on frozen or paraffin sections.
Western blot: 0.5-1 μg/mL
Optimal working dilutions must be determined by the end user.
Western blot: 0.5-1 μg/mL
Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Biochem/physiol Actions
Recognizes alpha synuclein.
Physical form
Affinity purified immunoglobulin in PBS containing 0.02% sodium azide. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.
Preparation Note
Maintain lyophilized material at -70°C (dry) for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles.
Other Notes
Replaces: 04-1053
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lojze M Smid et al.
Journal of Alzheimer's disease : JAD, 36(2), 261-274 (2013-04-10)
This work is aimed at correlating pre-mortem [18F]FDDNP positron emission tomography (PET) scan results in a patient with dementia with Lewy bodies (DLB), with cortical neuropathology distribution determined postmortem in three physical dimensions in whole brain coronal sections. Analysis of
Hazel L Roberts et al.
PloS one, 12(2), e0171925-e0171925 (2017-02-12)
α-Synuclein misfolding and aggregation is often accompanied by β-amyloid deposition in some neurodegenerative diseases. We hypothesised that α-synuclein promotes β-amyloid production from APP. β-Amyloid levels and APP amyloidogenic processing were investigated in neuronal cell lines stably overexpressing wildtype and mutant
Ivani Brys et al.
The European journal of neuroscience, 46(3), 1906-1917 (2017-04-04)
Parkinson's disease (PD) is a neurodegenerative disorder characterised by progressive motor symptoms resulting from chronic loss of dopaminergic neurons in the nigrostriatal pathway. The over expression of the protein alpha-synuclein in the substantia nigra has been used to induce progressive
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| AB5334P | 04053252362903 |
| AG240 | 04053252281068 |